Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

avagacestat

Known as: (2R)-2-(N-((4-Chlorophenyl)sulfonyl)-N-((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoropentanamide, Pentanamide, 2-(((4-chlorophenyl)sulfonyl)((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoro-, (2R)- 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
IMPORTANCE Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to… Expand
2015
2015
Hepatic stellate cells (HSCs) known as “master producers” and macrophages as “master regulators”, are the key cell types that… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2014
Review
2014
The prevailing theory regarding Alzheimer disease (AD) is that insoluble amyloid β‐peptide (Aβ) plays a critical role in the… Expand
Highly Cited
2013
Highly Cited
2013
A hallmark of Alzheimer’s disease (AD) pathology is the accumulation of brain amyloid β-peptide (Aβ), generated by γ-secretase… Expand
  • table 1
Highly Cited
2012
Highly Cited
2012
OBJECTIVE To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
2012
Highly Cited
2012
BACKGROUND γ-Secretase inhibitors (GSIs) are being investigated for their potential to modify the progression of Alzheimer… Expand
2012
2012
Background and ObjectivesAvagacestat is an orally active γ-secretase inhibitor that selectively inhibits amyloid β (Aβ) synthesis… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2012
2012
BackgroundThe concentration of amyloid β (Aβ) peptides in cerebrospinal fluid (CSF) is a biomarker for Alzheimer’s disease (AD… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2012
Highly Cited
2012
The "Notch-sparing" γ-secretase inhibitor (GSI) BMS-708,163 (Avagacestat) is currently in phase II clinical trials for Alzheimer… Expand
  • figure 1
  • table 1
  • figure 2
2012
2012
Background The concentration of amyloid b (Ab) peptides in cerebrospinal fluid (CSF) is a biomarker for Alzheimer’s disease (AD… Expand